Market Price

Price is unknown


Stock Analyzer Tutorials

S2O Stock Analyzer - General Info

General Info


type: video (mp4); length: 3:30

Demonstrates how to use Stock Analyzer, shows how to analyze a stock and explains in detail "General Info" section of the Stock Analyzer result page.

S2O Stock Analyzer - Financial Statements

Financial Statements


type: video (mp4); length: 5:10

Explains information presented in the Financial Statements section of the S2O Stock Analyzer: financial statements charts, absolute values and growth rates.

S2O Stock Analyzer - Growth Grade and Financial Ratios

Growth Grade and Financial Ratios


type: video (mp4); length: 5:09

Demonstrates how to use Growth Grade & Financial Ratios section; shows the difference between historical and year-over-year Growth Grade on the real life example.

S2O Stock Analyzer - Value Price

Value Price


type: video (mp4); length: 6:03

Demonstrates how to use Value Price (intrinsic value) and the Graham Number, MOS (margin of safety) and IRT - Investment Recovery Time; explains 3 different projection models used to compute value price - pessimistic, moderate and optimistic.

S2O Stock Analyzer - Price Charts

Price Charts


type: video (mp4); length: 8:34

Demonstrates basic rules of how to read a candlestick chart, long and short term moving averages, stochastic, MACD and relative strength (RS) charts. Explains how bull or bear market condition is computed.

General Info

Shire plc, a biotechnology company, researches, develops, licenses, manufactures, markets, distributes, and sells medicines for rare diseases and other specialized conditions worldwide. The company offers products in therapeutic areas, including hematology, genetic diseases, neuroscience, immunology, internal medicine, ophthalmology, and oncology. Its marketed products include ADVATE, ADYNOVATE/ADYNOVI, and OBIZUR for the treatment of hemophilia A; RIXUBIS to treat hemophilia B; VONVENDI for the treatment of von willebrand disease; FEIBA to treat hemophilia A and B patients with inhibitors; ELAPRASE to treat hunter syndrome; REPLAGAL for fabry disease; and VPRIV to treat type 1 Gaucher disease. The company's marketed products also comprise VYVANSE/VENVANSE/ELVANSE/TYVENSE/VUXEN/ADUVANZ for the treatment of attention deficit/hyperactivity disorder (ADHD) and binge eating disorder; ADDERALL XR and MYDAYIS to treat ADHD; GAMMAGARD LIQUID/KIOVIG, GAMMAGARD S/D, HYQVIA, and CUVITRU for the treatment of primary immunodeficiency; and FLEXBUMIN to treat hypovolemia and hypoalbuminemia. In addition, its marketed products consists of CINRYZE and FIRAZYR for the treatment of hereditary angioedema; FOSRENOL to treat hyperphosphatemia; LIALDA/MEZAVANT and PENTASA for ulcerative colitis; GATTEX/REVESTIVE for the treatment of short bowel syndrome; NATPARA for the control of hypocalcemia in patients with hypoparathyroidism; ONCASPAR to treat acute lymphoblastic leukemia; ONYVIDE for metastatic adenocarcinoma of the pancreas; and XIIDRA for the treatment of dry eye disease. The company markets its products through wholesalers, distributors, and pharmacies. It has collaborative and other licensing arrangements with Rani Therapeutics LLC; Parion Sciences Inc.; Pfizer Inc.; Precision BioSciences Inc.; Symphogen; and Ipsen Bioscience Inc., as well as a preclinical research collaboration agreement with NanoMedSyn. The company was founded in 1986 and is headquartered in Dublin, Ireland.

Financial Statements

The charts below show selected Annual and Quarterly Financial Data.

The purpose of these charts is to discover long and short term change dynamics. When numbers are growing year after year in the annual statements chart, the business become stronger and stronger and this is a good sign.

Quarterly Data Chart can be used to do a short term analysis. It makes sense to pay attention to the quarterly dynamics and do not wait for the next yearly statement. We should be alerted if we see that quarterly numbers are going down.

You can check "Annual Financial Statements" and "Quarterly Financial Statements" sections for exact numbers and growth rates.

Annual Statements

On a charts below the Line shows absolute values and the Bar chart shows Year-Over-Year Growth Rate for selected financial statement item. A consistent GROWTH is generally considered necessary to fund future growth from within a business.
NOTE: Growth Rate is not provided if either the latest period or the year-ago period contains a net loss. (source: WSJ Digest of Earnings)
TIP! move your mouse pointer over bar or a circle on any chart below to see details.

Financial Statements

Income Statement



 

Cash Flow Statement



 

Balance Sheet



 

Liquidity Ratios

Current Ratio


 

Current Ratio measures the ability to meet short term obligations. Generally accepted standard is 2 (current assets should be 2 times or 200% of current liabilities).

Quick Ratio


 

Measures immediate liquidity or the cash available to cover immediate liabilities. A safe margin would be at least 1 (100%).

Financial Leverage


 

Defined as total assets divided by total shareholders' equity. The higher the ratio, the more debt a company uses in its capital structure.

Profitability Ratios

ROA


 

Return on Assets (ROA) measures the income (profit) that is generated by the use of the assets of the business.

ROE


 

Return on Equity (ROE) is a measure of profitability that calculates how many dollars of profit a company generates with each dollar of shareholders equity. ROE is sometimes called "return on net worth."

ROIC


 

The Return on Invested Capital (ROIC) measure gives a sense of how well a company is using its money to generate returns. Some investors use this figure as a final evaluation to determine whether or not to invest in a company.

Annual Statements

Item Name Dec '07 Dec '08 Dec '09 Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17
Equity (BVPS) 6.58
6.95
10.22
13.08
15.76
20.32
21.41
33.33
48.37
98.82
107.81
growth rate 5.6% 47.1% 28.0% 20.5% 28.9% 5.4% 55.7% 45.1% 104.3% 9.1%
Earnings BIT -1,400.00
265.60
643.00
769.30
1,090.00
911.40
1,690.00
2,231.70
2,217.30
3,078.60
4,165.00
growth rate 100.0% 142.1% 19.6% 41.7% -16.4% 85.4% 32.1% -0.7% 38.8% 35.3%
Avg.PE -25.90
46.95
21.28
22.94
22.94
24.45
19.57
14.00
24.42
145.97
25.33
growth rate 100.0% -54.7% 7.8% 0.0% 6.6% -20.0% -28.5% 74.4% 497.8% -82.7%
ROA -37.92
3.78
11.50
11.75
14.70
10.88
8.51
31.02
8.62
0.78
6.34
growth rate 100.0% 204.2% 2.2% 25.1% -26.0% -21.8% 264.5% -72.2% -91.0% 712.8%
ROE -91.62
12.36
30.63
26.95
30.69
21.31
14.50
48.55
14.10
1.69
13.12
growth rate 100.0% 147.8% -12.0% 13.9% -30.6% -32.0% 234.8% -71.0% -88.0% 676.3%
ROIC -52.71
9.48
18.97
18.53
20.00
16.84
13.53
43.38
12.76
2.09
7.67
growth rate 100.0% 100.1% -2.3% 7.9% -15.8% -19.7% 220.6% -70.6% -83.6% 267.0%
Cur. Ratio 1.34
1.27
1.54
1.45
0.87
1.95
2.37
1.72
0.61
0.97
0.97
growth rate -5.2% 21.3% -5.8% -40.0% 124.1% 21.5% -27.4% -64.5% 59.0% 0.0%
Quick Ratio 0.98
0.74
1.07
0.96
0.58
1.40
1.77
1.33
0.36
0.41
0.44
growth rate -24.5% 44.6% -10.3% -39.6% 141.4% 26.4% -24.9% -72.9% 13.9% 7.3%
Leverage 3.52
3.03
2.41
2.20
2.00
1.92
1.55
1.57
1.69
2.32
1.87
growth rate -13.9% -20.5% -8.7% -9.1% -4.0% -19.3% 1.3% 7.6% 37.3% -19.4%
Balance Sheet Dec '07 Dec '08 Dec '09 Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17
Acct.Receivable 395.00
597.50
692.50
1,052.60
976.00
1,153.00
1,170.40
1,293.00
3,083.30
3,352.60
growth rate 51.3% 15.9% 52.0% -7.3% 18.1% 1.5% 10.5% 138.5% 8.7%
Acct.Payable 1,370.50
208.00
203.00
247.70
441.40
911.90
914.60
growth rate -84.8% -2.4% 22.0% 78.2% 106.6% 0.3%
Cur.Assets 1,044.40
1,570.20
1,880.30
2,208.20
3,212.00
4,288.00
5,183.10
2,255.50
7,539.50
7,608.40
growth rate 50.3% 19.8% 17.4% 45.5% 33.5% 20.9% -56.5% 234.3% 0.9%
Total Assets 3,933.70
4,617.50
5,387.60
6,380.20
7,317.00
8,323.00
13,632.10
16,609.80
67,035.40
67,756.90
growth rate 17.4% 16.7% 18.4% 14.7% 13.8% 63.8% 21.8% 303.6% 1.1%
Cash 218.20
498.90
550.60
640.60
1,482.00
2,239.00
2,982.40
135.50
528.80
472.40
growth rate 128.6% 10.4% 16.4% 131.4% 51.1% 33.2% -95.5% 290.3% -10.7%
Inventory 154.50
189.70
260.00
340.10
437.00
455.00
544.80
635.40
3,562.30
3,291.50
growth rate 22.8% 37.1% 30.8% 28.5% 4.1% 19.7% 16.6% 460.6% -7.6%
Cur.Liabilities 823.80
1,020.00
1,293.30
2,534.30
1,646.00
1,808.00
3,021.90
3,706.10
7,743.30
7,882.00
growth rate 23.8% 26.8% 96.0% -35.1% 9.8% 67.1% 22.6% 108.9% 1.8%
Liabilities 2,635.20
2,705.00
2,936.20
3,195.20
3,508.00
2,957.00
4,969.20
6,780.70
38,087.40
31,580.50
growth rate 2.7% 8.6% 8.8% 9.8% -15.7% 68.1% 36.5% 461.7% -17.1%
LT Debt 1,130.00
1,143.10
1,143.60
1,107.90
0.00
1,100.00
0.00
82.10
69.90
19,552.60
16,410.70
growth rate 1.2% 0.0% -3.1% -100.0% -100.0% -14.9% 27,872.3% -16.1%
Equity 1,227.00
1,297.90
1,912.50
2,451.40
3,185.00
3,809.20
5,366.00
8,662.90
9,829.10
28,948.00
36,176.40
growth rate 5.8% 47.4% 28.2% 29.9% 19.6% 40.9% 61.4% 13.5% 194.5% 25.0%
Common Shares 180.00
182.00
183.00
187.00
198.00
198.00
197.00
197.00
197.00
259.00
304.00
growth rate 1.1% 0.6% 2.2% 5.9% 0.0% -0.5% 0.0% 0.0% 31.5% 17.4%
Cash Flow Statement Dec '07 Dec '08 Dec '09 Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17
Capital Expenditures 169.40
234.20
254.40
324.30
194.30
150.00
157.00
114.70
114.70
648.70
798.80
growth rate 38.3% 8.6% 27.5% -40.1% -22.8% 4.7% -26.9% 0.0% 465.6% 23.1%
Cash Dividends 41.30
46.80
54.40
62.00
73.80
86.30
96.40
121.20
134.40
171.30
281.30
growth rate 13.3% 16.2% 14.0% 19.0% 16.9% 11.7% 25.7% 10.9% 27.5% 64.2%
Cash From OA 474.70
800.10
626.90
954.90
1,073.60
1,383.00
1,463.00
4,228.40
2,337.00
2,658.90
4,256.70
growth rate 68.6% -21.7% 52.3% 12.4% 28.8% 5.8% 189.0% -44.7% 13.8% 60.1%
FCF per Share 1.70
2.97
2.00
3.18
4.04
6.01
5.38
11.05
20.47
7.88
10.08
growth rate 74.7% -32.7% 59.0% 27.0% 48.8% -10.5% 105.4% 85.3% -61.5% 27.9%
Sale Purchase of Stock -138.40
-189.60
-226.60
17.40
16.60
169.20
134.10
growth rate 0.0% 0.0% 100.0% -4.6% 919.3% -20.7%
FCF 305.00
539.00
366.00
626.00
874.00
1,189.00
1,306.00
4,151.00
2,222.00
2,010.00
3,458.00
growth rate 76.7% -32.1% 71.0% 39.6% 36.0% 9.8% 217.8% -46.5% -9.5% 72.0%
Income Statement Dec '07 Dec '08 Dec '09 Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17
Sales 2,440.00
3,022.20
3,007.70
3,471.10
4,158.10
4,527.00
4,934.00
6,022.10
6,416.70
11,396.60
15,160.60
growth rate 23.9% -0.5% 15.4% 19.8% 8.9% 9.0% 22.1% 6.6% 77.6% 33.0%
Op.Income 412.00
620.20
794.10
882.70
806.00
1,420.00
2,231.70
2,217.30
3,078.60
4,165.00
growth rate 50.5% 28.0% 11.2% -8.7% 76.2% 57.2% -0.7% 38.8% 35.3%
IBT 265.60
643.00
769.30
1,117.10
1,025.90
1,709.50
3,338.90
1,383.60
477.40
1,895.90
growth rate 142.1% 19.6% 45.2% -8.2% 66.6% 95.3% -58.6% -65.5% 297.1%
Net Income 156.00
491.60
588.00
882.70
806.00
1,420.00
3,405.50
1,303.40
327.40
4,271.50
growth rate 215.1% 19.6% 50.1% -8.7% 76.2% 139.8% -61.7% -74.9% 1,204.7%
EPS -8.06
0.85
2.69
3.15
4.53
3.93
3.52
17.28
6.60
1.26
14.04
growth rate 100.0% 216.5% 17.1% 43.8% -13.3% -10.4% 390.9% -61.8% -80.9% 1,014.3%
Gross Profit 2,097.10
2,614.20
2,619.70
3,007.70
3,606.40
3,942.00
4,264.00
5,134.70
5,478.80
8,698.10
11,207.60
growth rate 24.7% 0.2% 14.8% 19.9% 9.3% 8.2% 20.4% 6.7% 58.8% 28.9%
R&D 526.60
639.90
661.50
764.50
953.00
933.40
877.20
920.30
1,430.90
1,743.30
growth rate 21.5% 3.4% 15.6% 24.7% -2.1% -6.0% 4.9% 55.5% 21.8%

Quarterly Statements

Item Name Sep '17 Dec '17 Mar '18 Jun '18 Sep '18
Earnings BIT 951.30
1,150.60
972.80
1,019.80
1,037.90
growth rate 21.0% -15.5% 4.8% 1.8%
Balance Sheet Sep '17 Dec '17 Mar '18 Jun '18 Sep '18
Acct.Receivable 2,936.30
3,352.60
3,289.60
3,061.10
3,263.00
growth rate 14.2% -1.9% -7.0% 6.6%
Acct.Payable 3,863.50
914.60
3,939.00
3,888.50
4,025.10
growth rate -76.3% 330.7% -1.3% 3.5%
Cur.Assets 7,291.50
7,608.40
7,915.00
9,788.40
7,799.30
growth rate 4.4% 4.0% 23.7% -20.3%
Total Assets 67,476.50
67,756.90
67,868.80
66,222.10
63,765.90
growth rate 0.4% 0.2% -2.4% -3.7%
Cash 209.30
472.40
317.70
259.70
193.20
growth rate 125.7% -32.8% -18.3% -25.6%
Inventory 3,427.30
3,291.50
3,340.80
3,353.30
3,458.70
growth rate -4.0% 1.5% 0.4% 3.1%
Cur.Liabilities 7,461.10
7,882.00
6,944.60
6,307.30
8,511.60
growth rate 5.6% -11.9% -9.2% 35.0%
Liabilities 34,821.90
31,580.50
30,468.80
29,461.70
26,475.70
growth rate -9.3% -3.5% -3.3% -10.1%
LT Debt 17,613.90
16,410.70
16,391.80
16,383.20
10,740.70
growth rate -6.8% -0.1% -0.1% -34.4%
Equity 32,654.60
36,176.40
37,400.00
36,760.40
37,290.20
growth rate 10.8% 3.4% -1.7% 1.4%
Common Shares 81.50
81.60
81.70
81.90
81.90
growth rate 0.1% 0.1% 0.2% 0.0%
Cash Flow Statement Sep '17 Dec '17 Mar '18 Jun '18 Sep '18
Capital Expenditures 174.40
233.30
177.80
183.50
203.30
growth rate 33.8% -23.8% 3.2% 10.8%
Cash Dividends 46.60
46.60
276.60
276.60
growth rate 0.0% 493.6% 0.0%
Cash From OA 1,055.20
1,519.60
1,010.30
939.60
857.60
growth rate 44.0% -33.5% -7.0% -8.7%
Sale Purchase of Stock 12.70
41.90
40.50
growth rate 229.9% -3.3%
FCF 880.80
1,286.30
832.50
756.10
654.30
growth rate 46.0% -35.3% -9.2% -13.5%
Income Statement Sep '17 Dec '17 Mar '18 Jun '18 Sep '18
Sales 3,697.60
4,144.90
3,765.70
3,919.50
3,871.70
growth rate 12.1% -9.2% 4.1% -1.2%
Op.Income 951.30
1,150.60
972.80
1,019.80
1,037.90
growth rate 21.0% -15.5% 4.8% 1.8%
IBT 564.70
703.80
593.90
739.90
740.50
growth rate 24.6% -15.6% 24.6% 0.1%
Net Income 550.80
3,105.40
550.60
615.50
537.20
growth rate 463.8% -82.3% 11.8% -12.7%
EPS
growth rate
Gross Profit 2,696.20
2,940.50
2,666.80
2,811.20
2,714.10
growth rate 9.1% -9.3% 5.4% -3.5%
R&D 402.80
418.80
405.20
427.60
407.20
growth rate 4.0% -3.3% 5.5% -4.8%

Growth Grade & Financial Ratios

All financial ratios below are calculated based on latest annual statements available and present the most up to date snapshot of a company finances.

Growth Grade

Historical Growth Grade:

A (87.84)

YOY Growth Grade:

C (61.34)

Click on buttons above for detailed yearly growth rates.

Market Ratios

Profitability Ratios

Liquidity Ratios

Efficiency Ratios

Value Price

PE and EPS

Historical Current Forward
PE 11.38 11.38 11.38
EPS / Growth 18.9% 15.74 9.8%

Value Price & Investment Recovery Time

Read more about Stock2Own value price in Stock Market: Fundamental Analysis.

Equity Growth Rate: 50.0%

Estimates Pessimistic Moderate Optimistic My Numbers
Rate of Return 15.0%
MOS Price % 50 %
Future EPS Growth 9.8% 26.2% 27.0%
Future PE 11.38 11.38 25.57
Future EPS 40.10 161.84 171.58
Value Price
MOS %
112.78
455.22
1,084.59
MOS Price 56.39 227.61 542.29
IRT

Graham Number:

NOTE: The Graham Number applies only to certain types of stocks in combination with a number of other criteria.

Read more about Graham Number in Stock Market: Fundamental Analysis.

Price Chart

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.

Risk / Reward Ratios

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.